Puma Biotechnology (PBYI) PT Lowered to $87 at Stifel
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Buy the Puma Biotechnology (PBYI) Dip - Citi
May 10, 2018 12:32 PM EDTCiti analyst Yigal Nochomovitz came out to defend Puma Biotechnology (NASDAQ: PBYI), saying the sell-off is overdone and to buy the dip.
He said the Possible explanations in order of likelihood 1) Lower apparent demand (NRx / new specialty pharmacy pt adds) in April (~230 / 280) vs. March (~300 / 342), 2)... More
Puma Biotechnology (PBYI) PT Lowered to $111 at BofA/Merrill Lynch
May 10, 2018 6:28 AM EDTBofA/Merrill Lynch lowered its price target on Puma Biotechnology (NASDAQ: PBYI) to $111.00 (from $115.00) while maintaining a Buy rating.
... MorePuma Biotech (PBYI) Tops Q1 EPS by 24c
May 9, 2018 4:10 PM EDTPuma Biotech (NASDAQ: PBYI) reported Q1 EPS of ($0.65), $0.24 better than the analyst estimate of ($0.89).
For earnings history and earnings-related data on Puma Biotech (PBYI) click here.
... More